

Characterization of Carbapenemase Genes in *Enterobacteriaceae* Species Exhibiting Decreased Susceptibility to Carbapenems in a University Hospital in Chongqing, China

Yun Xia, Ph.D., Zhenzhen Liang, M.D., Xiaoyan Su, M.D., and Ying Xiong, M.D.

Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Background: Our study was to investigate the prevalence of carbapenemase genes in strains of *Enterobacteriaceae* species exhibiting decreased susceptibility to carbapenems in our hospital.

Methods: The carbapenemase producing *Enterobacteriaceae* species were confirmed by modified Hodge test (MHT) and EDTA-disc synergy test which indicating the production of class B carbapenemases. PCR and sequencing analysis were used to identify the drug-resistant genes. DNA fingerprinting based on enterobacterial repetitive intergenic consensus (ERIC)-PCR was applied to investigate the homology of *Enterobacteriaceae* species.

Results: From a collection of 1,472 *Enterobacteriaceae* species, 18 isolates with decreased susceptibility to carbapenem treatment were identified and 9 of which were positive by MHT, and 6 of which produced class B carbapenemases. PCR and sequencing analysis of the 18 isolates revealed 4 different carbapenemase genes (*bla*_{IMP-8}, *bla*_{oxa-1}, *bla*_{IMP-26}, and *bla*_{oxa-47}) in 10 isolates, with the *bla*_{IMP-8} and *bla*_{oxa-1} genes being the most common (60-70% prevalence). ERIC-PCR showed 5, 2, and 2 unique genotypes for *Enterobacter cloacae*, *Escherichia coli*, and *Klebsiella pneumoniae*, respectively. Three *E. coli* strains isolated from different patients from the urologic surgery department exhibited the same DNA banding pattern, suggesting a possible clonal dissemination. Majority (17/18) of the carbapenem-unsusceptible *Enterobacteriaceae* species isolates was obtained from the surgery department of our hospital.

Conclusions: The main carbapenemase genes of *Enterobacteriaceae* species in our hospital were *bla*_{IMP-8} and *bla*_{oxa-1}. Prevalence of carbapenem resistance may be existed in surgery department and infection control should be taken for preventing further dissemination of drug-resistant strains.

Key Words: *Enterobacteriaceae* species, Carbapenemases, Carbapenems

Received: January 26, 2012

Revision received: March 4, 2012

Accepted: May 25, 2012

Corresponding author: Yun Xia
Department of Clinical Laboratory Medicine,
The First Affiliated Hospital of Chongqing
Medical University, You Yi Road 1#, Yu
Zhong District, Chongqing 400016, China
Tel: +86-23-89012742
Fax: +86-23-89012513
E-mail: xiayun12cn@yahoo.com.cn

© The Korean Society for Laboratory Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Enterobacteriaceae species are among the most common nosocomial pathogens, causing serious infections in various organs and tissues. Currently, carbapenems are the most potent agents

prescribed for the treatment of serious infections caused by *Enterobacteriaceae* species because of their broad spectra of antibacterial activity and their excellent stability to hydrolysis by most β -lactamases, including extended-spectrum β -lactamases (ESBLs) and AmpC cephalosporinases. However, the wide-

spread use of carbapenems has led to the emergence of carbapenem-resistant *Enterobacteriaceae* species in diverse geographic locations worldwide, and this is becoming an important therapeutic challenge in the clinic setting [1-3].

The main mechanisms of carbapenem resistance in *Enterobacteriaceae* species include the acquisition of carbapenemases and hyperproduction of AmpC cephalosporinases, in combination with porin loss [4]. Carbapenemases are members of the molecular class A, B, and D β -lactamases, which have the ability to hydrolyze penicillins, cephalosporins, monobactams, and carbapenems [4]. Class A serine carbapenemases include 3 major families of NMC/IMI, SME, and KPC enzymes and can be inhibited by clavulanic acid and tazobactam [5]. Among the class A carbapenemases, KPC-2 is the most common type reported in China [6, 7]. Class B carbapenemases, also called metallo- β -lactamases (MBLs), are resistant to the commercially available β -lactamase inhibitors, such as clavulanic acid, sulbactam, and tazobactam, but susceptible to inhibition by metal ion chelators, such as EDTA, a chelator of Zn^{2+} and other divalent cations [8]. In the past decade, a number of acquired MBLs have been identified and categorized into 2 major groups: IMP- and VIM-type enzymes. IMP-4 and IMP-8 carbapenemases have been detected in China, and these have led to a low to moderate level of carbapenem resistance in strains of *Enterobacteriaceae* species [9]. The hydrolysis of carbapenems by the class D oxacillinase family is weak and leads to reduced susceptibility to imipenem and meropenem but with the minimal inhibitory concentration (MIC) still in the susceptible range, thus potentially causing detection failures [10].

The goals of this study were to investigate the prevalence of carbapenemase genes in clinical strains of *Enterobacteriaceae* species isolated from a university hospital, and to explore the main mechanisms of decreased susceptibility to carbapenems in these clinical strains.

METHODS

1. Bacterial strains and susceptibility tests

All patient specimens utilized in this study were from The First Affiliated Hospital of Chongqing Medical University, which has 2,500 inpatient beds and is one of the largest hospitals in the southwest of China. Samples were collected from November 2009 to December 2010. The clinical isolates were identified and the susceptibility tests were performed by using the Vitek2 Compact System with GN card and ASTGN13 card (bioMérieux, Marcy l'Etoile, France). Strains of *Enterobacteriaceae* species

with decreased susceptibility to carbapenems (MIC of imipenem, meropenem, or ertapenem ≥ 2 $\mu\text{g/mL}$) were consecutively collected and confirmed by the agar dilution method, according to the guidelines of the CLSI [11].

2. Detection of carbapenemases

Modified Hodge Tests (MHT) were carried out according to CLSI recommendations for phenotypic screening of carbapenemase producers among species of *Enterobacteriaceae* [11]. *Escherichia coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC BAA-1705 were used as negative and positive controls, respectively. The class A and B carbapenemases were screened by clavulanic acid-disc synergy tests and EDTA-disc synergy tests, respectively, as previously described [12, 13].

3. PCR amplification and DNA sequencing

Total DNA was extracted from all strains by 10 min boiling of bacterial culture, followed by 1 min centrifugation at 15,000 rpm. The supernatant was collected and used for PCR amplification. The main class A, class B, and class D carbapenemase genes were amplified using the primers and conditions described in the references listed in Table 1 [14-19]. In addition, 3 ESBL genes (*bla*SHV, *bla*TEM, and *bla*CTX-M) and 5 plasmid-mediated AmpC cephalosporinase genes (*bla*CYM-2, *bla*ACT-1, *bla*ACC-1, *bla*DHA-1, and *bla*FOX-1) were amplified by PCR as previously described [20, 21], and all PCR products were sequenced directly in an ABI PRISM 3730XL sequencer (Applied

Table 1. Oligonucleotides used as primers for PCR and sequencing in this study

Class	Target	Sequence (5'-3')	Amplicon size (bp)	Reference
Class A	SME	Forward: AACGGCTTCATTTTGTITAG	820	14
		Reverse: GCTTCGCAATAGTTTTATCA		
	KPC	Forward: ATGTCACGTATCGCCGTCT	892	15
		Reverse: TTTTCAGAGCCTTACTGCC		
Class B	IMP	Forward: CATGGTTGGTGGTCTTGT	488	16
		Reverse: ATAATTTGGCGGACTTTGGC		
	VIM	Forward: AGTGGTGAGTATCCGACA	280	17
		Reverse: ATGAAAGTGCCTGGAGAC		
	NDM-1	Forward1: GGCGGAATGGCTCATCACGA	287	18
		Reverse1: CGCAACACAGCCTGACTTTC		
		Forward2: CAGCACACTTCTATCTC	293	18
		Reverse2: CCGCAACCATCCCCTCTT		
Class D	OXA	Forward: TTTTCTGTTGTTGGGTTTT	519	19
		Reverse: TTTCTTGGCTTTTATGCTTG		

Biosystems, Foster City, CA, USA). DNA sequences were compared with known sequences in GenBank.

4. Strain genotyping

We performed genotyping on all isolates, except for *Enterobacter amnigenus*, by using enterobacterial repetitive intergenic consensus (ERIC)-PCR with primers ERIC1R (5'-ATGTAAGCTCCTGGGGATTACAC-3') and ERIC2 (5'-AAGTAAGTGACTGGGGT-GAGCG-3') as previously described [22]. Electrophoretic banding patterns were compared by visual inspection. Isolates were considered different if their profiles differed by 2 or more bands [23].

RESULTS

1. Identification of *Enterobacteriaceae* species with decreased susceptibility to carbapenems

From a collection of 1,472 isolates of *Enterobacteriaceae* species, we identified 18 isolates with decreased susceptibility to carbapenem treatment, including 8 isolates of *Enterobacter cloacae*, 5 isolates of *E. coli*, 4 isolates of *K. pneumoniae*, and 1 isolate of *E. amnigenus* (Table 2). The rate of non-susceptibility to carbapenems was 1.22%. Fifteen of the 18 isolates (83.3%) were resistant to ertapenem (≥ 8 mg/L) and only 2 of the 18 isolates (11.1%) were resistant to imipenem (≥ 16 mg/L). All of the isolates exhibited multidrug-resistance to the antibiotics tested (data not shown).

2. Screening of carbapenemases

Of the 18 carbapenem-resistant isolates, 9 tested positive in MHT and 6 positive in the EDTA-disc synergy tests, indicating the production of class B carbapenemases in these strains (Table 2). None of them tested positive in the clavulanic acid-disc synergy tests, indicating the absence of class A carbapenemases.

3. PCR amplification and sequence analysis

Carbapenemase genes were detected in 10 of the 18 carbapenem-resistant isolates; the genes included the *bla*_{IMP-8} gene from 4 *E. cloacae* isolates and 2 *K. pneumoniae* isolates; the *bla*_{IMP-26} gene from 1 *E. cloacae* isolate; the *bla*_{oxa-1} gene from 5 *E. cloacae* isolates and 2 *E. coli* isolates; and the *bla*_{oxa-47} gene from 2 *K. pneumoniae* isolates (Table 2). We failed to detect *bla*_{SME}, *bla*_{KPC}, *bla*_{NDM-1}, or *bla*_{VIM} type carbapenemase genes in these 18 isolates. ESBL genes were found in all the isolates except for the 2 *E. cloacae* isolates that harbored the *bla*_{IMP-8} gene. AmpC cephalosporinase genes were detected in 7 of the 18 isolates: including the

*bla*_{DHA-1} gene from 2 *K. pneumoniae* isolates; the *bla*_{ACT-1} gene from 1 *E. cloacae* isolate and 1 *E. amnigenus* isolate; and the *bla*_{CMY-2} gene from 3 *E. coli* isolates. All the AmpC-positive strains, except for 1 *E. cloacae* strain (No. 1), did not harbor carbapenemase genes.

4. Strain genotyping and epidemiological association

Genetic relatedness of all the isolates, except for *E. amnigenus*, was investigated by ERIC-PCR typing. Five distinct ERIC profiles were observed amongst 8 strains of *E. cloacae*, and no obvious clonal association was observed within these strains. Five strains of *E. coli* exhibited 2 distinct ERIC profiles, and the 3 strains presenting the same profile, i.e. showing clonal association, were all isolated from the urologic surgery department. Four strains of *K. pneumoniae* showed 2 ERIC profiles and an epidemiological relationship was not found (Fig. 1). However, the 2 strains with identical carbapenemase genes, ESBL and AmpC cephalosporinase, exhibited the same ERIC profile.

DISCUSSION

Since the widespread use of carbapenems in the clinic, carbapenem-resistant *Enterobacteriaceae* species have been detected increasingly worldwide, and a similar trend has been observed in China [9]. Effective and accurate screening for *Enterobacteriaceae* species with decreased susceptibility to carbapenems is important in routine clinical microbiology tests. In this study, we found that the resistance rate of ertapenem was much higher than that of imipenem (83.3% vs. 11.1%, $P < 0.01$) in the *Enterobacteriaceae* species isolates studied, indicating that ertapenem was more sensitive than imipenem in the screening of carbapenem-unsusceptible *Enterobacteriaceae* species isolates [11]. Nine of 10 strains of *Enterobacteriaceae* species with carbapenemase genes tested positive in MHT, while none of the strains without any carbapenemase genes tested positive in MHT. The sensitivity and specificity of MHT were 90% and 100%, respectively. Six of 7 strains of *Enterobacteriaceae* species with class B carbapenemase tested positive in the EDTA-disc synergy tests, while none of the strains without class B carbapenemase genes tested positive in the EDTA-disc synergy tests. The sensitivity and specificity of the EDTA-disc synergy tests for MBLs detection were 85.7% and 100%, respectively.

In the 10 strains of *Enterobacteriaceae* species with carbapenemase genes, 4 strains harbored the *bla*_{IMP-8} and *bla*_{oxa-1} genes, 2 strains harbored the *bla*_{IMP-8} and *bla*_{oxa-47} genes, and 3 strains harbored the *bla*_{oxa-1} gene alone. These results suggest that the

Table 2. Distribution and drug-resistant mechanisms of 18 strains of *Enterobacteriaceae* species

No.	Bacteria (isolation date)	Distribution	Sample	ETP (mg/L)	IMP (mg/L)	MHT	Carbapenemase genes	ESBLs genes	AmpC genes
1	<i>E. cloacae</i> (11/4/09)	Neurosurgery	Blood	≥8	2	+	IMP-8 OXA-1	CTX-M14	Act-1
2	<i>E. amnigenus</i> (12/15/09)	Center ICU	Secretion	≥8	8	-	Negative	CTX-M14	Act-1
3	<i>E. cloacae</i> (02/11/10)	Hepatobiliary surgery	Blood	≥8	≤1	+	IMP-8, TEM OXA-1	Negative	Negative
4	<i>E. cloacae</i> (04/23/10)	Center ICU	Urine	4	≤1	+	IMP-8 OXA-1	Negative	Negative
5	<i>E. cloacae</i> (05/17/10)	Outpatient	Secretion	≥8	8	-	Negative	CTX-M3	Negative
6	<i>E. cloacae</i> (06/09/10)	Orthopaedics	Tissue	>8	≤1	+	OXA-1	Negative	Negative
7	<i>E. cloacae</i> (07/22/10)	Surgery ICU	Bile	≥8	≤1	+	IMP-8 OXA-1	CTX-M14	Negative
8	<i>E. cloacae</i> (10/26/10)	Hepatobiliary surgery	Secretion	≥8	2	+	IMP-26	Negative	Negative
9	<i>E. cloacae</i> (11/20/10)	Center ICU	Urine	≥8	≤1	-	Negative	Negative	Negative
10	<i>E. coli</i> (04/15/10)	Urologic surgery	Calculus	≥8	≤1	-	Negative	CTX-M14	CYM-2
11	<i>E. coli</i> (04/27/10)	Urologic surgery	Urine	≥8	2	-	Negative	CTX-M14	CYM-2
12	<i>E. coli</i> (06/15/10)	Emergency medicine	Secretion	≥8	≥16	+	OXA-1	CTX-M14	Negative
13	<i>E. coli</i> (06/19/10)	Urologic surgery	Urine	≥8	≤1	-	Negative	CTX-M14	CYM-2
14	<i>E. coli</i> (03/24/10)	Orthopaedics	Secretion	4	≤1	-	OXA-1	Negative	Negative
15	<i>K. pneumoniae</i> (12/08/09)	Urologic surgery	Urine	4	2	+	IMP-8 OXA-47	CTX-M14, SHV11	Negative
16	<i>K. pneumoniae</i> (03/14/10)	Gastrointestinal surgery	Ascites	≥8	≤1	-	Negative	SHV11	DHA-1
17	<i>K. pneumoniae</i> (08/19/10)	Surgery ICU	Urine	≥8	≥16	+	IMP-8 OXA-47	CTX-M14, SHV11	Negative
18	<i>K. pneumoniae</i> (12/06/10)	Ophthalmology	Secretion	≥8	≤1	-	Negative	CTX-M14, SHV11	DHA-1

Abbreviations: *E. cloacae*, *Enterobacter cloacae*; *E. amnigenus*, *Enterobacter amnigenus*; *E. coli*, *Escherichia coli*; *K. pneumoniae*, *Klebsiella pneumoniae*; ETP, Ertapenem; IMP, Imipenem; MHT, modified Hodge test; ICU, intensive care unit.

most common carbapenemase-type genes in our hospital were *bla*_{IMP-8} (6/9) and *bla*_{OXA-1} (7/9). Class A carbapenemase genes and VIM and NDM-1 β-lactamase genes were not detected in

our hospital.

The *bla*_{IMP-8} gene, first found in *K. pneumoniae* in 2001, is very closely related to *bla*_{IMP-2} in DNA sequence, with only 4 nucleotide




Fig. 1. Representative gel showing banding profiles by ERIC-PCR. (A) *Enterobacter cloacae*; (B) *Escherichia coli*; (C) *Klebsiella pneumoniae*. The number below each lane corresponds to the strain number in Table 2. M: DNA molecular weight marker.

differences between them. This results in 2 amino acid changes. In contrast to the *bla*_{IMP-2} gene, which is located on the chromosome, the *bla*_{IMP-8} cassette is located on the plasmid, which would facilitate the spread of the resistance gene [24] and infection outbreak [25, 26]. Like *bla*_{IMP-8}, class D carbapenemase can only weakly hydrolyze imipenem. All strains with *bla*_{OXA} carbapenemase genes in our study were susceptible to imipenem except for one *E. coli* isolate (No.12), suggesting that this strain might have other drug-resistant mechanisms, such as loss or lower expression of major porins. In this study, we simultaneously detected *bla*_{IMP-8} and *bla*_{OXA-1} in 4 strains of *E. cloacae*. This observation has not been previously reported in China.

Biochemical analysis showed that CMY-2 and ACT-1 β -lactamase had a high catalytic efficiency towards imipenem, with low observed *K_m* values. CMY-2, ACT-1, and DHA-1 β -lactamases conferred a high level of resistance to ceftazidime and cefotaxime and significantly reduced the susceptibility to imipenem once expressed in *E. coli* HB4, whilst FOX-1 and ACC-1 enzymes did not confer resistance to imipenem [21]. In our study, 6 of the 9 MHT-negative strains expressed AmpC cephalosporinase genes, including *bla*_{ACT-1} in 1 *E. cloacae* strain, *bla*_{CMY-2} in 3 *E. coli* strains, and *bla*_{DHA-1} in 2 *K. pneumoniae* strains. The *bla*_{FOX-1} and *bla*_{ACC-1} genes were not found. This observation suggests that AmpC cephalosporinase hyperproduction may contribute to the resistance observed in these isolates [4]. Five strains were not found to contain any carbapenemase or AmpC cephalosporinase genes, implying that resistance in these strains may involve other mechanisms not investigated in this study.

ERIC-PCR studies demonstrated that the infections caused by 8 strains of *E. cloacae* were spontaneous, because of the absence of genetic relatedness between these strains. Three of 5 *E. coli* strains isolated from the urologic surgery ward showed the same genotype, suggesting a possible clonal dissemination of 1

strain. Although we did not find an obvious clonal association among 4 strains of *K. pneumoniae*, the finding of 2 strains with completely identical ERIC profile and drug-resistant gene profile suggests there is a possibility for these to become a clonal prevalence.

Interestingly, strains expressing the *bla*_{IMP} carbapenemase genes were not isolated from patients hospitalized in any department in the hospital except the department of surgery, and all the patients with positive of *bla*_{IMP} carbapenemase genes had received surgery. Surgery has been reported to be an important risk factor for the acquisition of MBL producers [25]. The finding of carbapenem-resistant isolates only in the department of surgery in our hospital may have important implications for the prevention and dissemination control of these drug-resistant pathogens. Because it is likely that the strains of *Enterobacteriaceae* species with decreased susceptibility to carbapenems might be prevalent in the department of surgery in our hospital, strict infection control measures should be implemented in order to prevent infection dissemination.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodríguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical *Escherichia coli* during therapy. *Int J Antimicrob Agents* 2008;32:534-7.
2. Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a *Klebsiella pneumoniae* clinical isolate is due to the combination of *bla*(ACT-1) β -lactamase production, porin OmpK35/36 inser-

- tional inactivation, and down-regulation of the phosphate transport porin phoe. *Antimicrob Agents Chemother* 2006;50:3396-406.
3. Vatopoulos A. High rates of metallo- β -lactamase-producing *Klebsiella pneumoniae* in Greece—a review of the current evidence. *Euro Surveill* 2008;13.pii:8023.
 4. Queenan AM and Bush K. Carbapenemases: the versatile β -lactamases. *Clin Microbiol Rev* 2007;20:440-58.
 5. Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A β -lactamases. *Biochem J* 1991;276:269-70.
 6. Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of *Serratia marcescens*, *Klebsiella pneumoniae*, and *Escherichia coli* isolates possessing the plasmid-mediated carbapenem-hydrolyzing β -lactamase KPC-2 in intensive care units of a Chinese hospital. *Antimicrob Agents Chemother* 2008;52:2014-8.
 7. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a *Klebsiella pneumoniae* isolate from China. *Antimicrob Agents Chemother* 2007;51:763-5.
 8. Walsh TR. The emergence and implications of metallo- β -lactamases in Gram-negative bacteria. *Clin Microbiol Infect* 2005;11(S6):2-9.
 9. Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M. Phenotypic and genotypic characterization of *Enterobacteriaceae* with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. *Antimicrob Agents Chemother* 2010;54:573-7.
 10. Cuzon G, Naas T, Boqaerts P, Glupczynski Y, Huang TD, Nordmann P. Plasmid-encoded carbapenem-hydrolyzing β -lactamase OXA-48 in an imipenem-susceptible *Klebsiella pneumoniae* strain from Belgium. *Antimicrob Agents Chemother* 2008;52:3463-4.
 11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 21st Informational supplement, M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
 12. Radice M, Power P, Gutkind G, Fernández K, Vay C, Famiglietti A, et al. First class a carbapenemase isolated from *enterobacteriaceae* in Argentina. *Antimicrob Agents Chemother* 2004;48:1068-9.
 13. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum GH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin Microbiol Infect* 2001;7:88-91.
 14. Queensn AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moelering RC Jr, et al. SME-type carbapenem-hydrolyzing class A β -lactamases from geographically diverse *Serratia marcescens* strains. *Antimicrob Agents Chemother* 2000;44:3035-9.
 15. Bratu S, Tolane P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. *J Antimicrob Chemother* 2005;56:128-32.
 16. Qi C, Malczynski M, Parker M, Scheetz MH. Characterization of genetic diversity of carbapenem-resistant *Acinetobacter baumannii* clinical strains collected from 2004 to 2007. *J Clin Microbiol* 2008;46:1106-9.
 17. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by *Pseudomonas aeruginosa* producing VIM-1 carbapenemase in Greece. *J Clin Microbiol* 2000;38:1290-2.
 18. Yong D, Toleman MA, Giske CG, Cho HS, Sundman S, Lee K, et al. Characterization of a new metallo- β -lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 2009;53:5046-54.
 19. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2004;48:15-22.
 20. Manoharan A, Premalatha K, Chatterjee S, Mathai D; SARI Group. Correlation of TEM, SHV and CTX-M extended-spectrum beta lactamases among *Enterobacteriaceae* with their in vitro antimicrobial susceptibility. *Indian J Med Microbiol* 2011;29:161-4.
 21. Mammeri H, Guillon H, Eb F, Nordmann P. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β -lactamases. *Antimicrob Agents Chemother* 2010;54:4556-60.
 22. Smith JL, Drum DJ, Dai Y, Kim JM, Sanchez S, Maurer JJ, et al. Impact of antimicrobial usage on antimicrobial resistance in commensal *Escherichia coli* strains colonizing broiler chickens. *Appl Environ Microbiol* 2007;73:1404-14.
 23. Khan AA, McCarthy S, Wang RF, Cerniglia CE. Characterization of United States outbreak isolates of *Vibrio parahaemolyticus* using enterobacterial repetitive intergenic consensus (ERIC) PCR and development of a rapid PCR method for detection of O3:K6 isolates. *FEMS Microbiol Lett* 2002;206:209-14.
 24. Yan JJ, Ko WC, Wu JJ. Identification of a plasmid encoding SHV-12, TEM-1, and a variant of IMP-2 metallo- β -lactamase, IMP-8, from a clinical isolate of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001;45:2368-71.
 25. Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrug-resistant *Klebsiella pneumoniae* carrying bla(IMP-8) in a university medical center in Taiwan. *J Clin Microbiol* 2001;39:4433-9.
 26. Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo- β -lactamase-producing *Enterobacteriaceae* isolates in a university hospital in Taiwan: prevalence of IMP-8 in *Enterobacter cloacae* and first identification of VIM-2 in *Citrobacter freundii*. *J Antimicrob Chemother* 2002;50:503-11.